Rigel Pharmaceuticals Inc. (New) (RIGL) Stock Price

RIGLStock

$46.48+18.24%52W

Market Cap$868.24M

P/E2.13x

PEG Ratio—

Div yield—

Beta1.21

RIGL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)22.76%

Price vs S&P 500 (4W)22.64%

VGM Score65.76

P/E Ratio (Annual)2.13x

P/CF (Annual)10.32x

Book Value / Share (Quarterly)$22.81

P/TBV (Annual)2.12x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)34.78%

Cash Flow / Share (Quarterly)$0.48

Price vs S&P 500 (YTD)-4.30%

Gross Margin (TTM)91.39%

Net Profit Margin (TTM)116.30%

EPS (TTM)$16.04

10-Day Avg Trading Volume0.36M

EPS Excl Extra (TTM)$16.04

Revenue Growth (5Y)22.06%

EPS (Annual)$19.48

ROI (Annual)82.71%

Gross Margin (Annual)93.33%

Net Profit Margin (5Y Avg)10.45%

Cash / Share (Quarterly)$5.11

P/E Basic Excl Extra (TTM)2.42x

Revenue Growth QoQ (YoY)-22.60%

P/E Normalized (Annual)2.13x

ROA (Last FY)71.46%

Revenue Growth TTM (YoY)3.31%

EBITD / Share (TTM)$4.49

ROE (5Y Avg)70.99%

Operating Margin (TTM)31.45%

Cash Flow / Share (Annual)$4.13

P/B Ratio1.83x

P/B Ratio (Quarterly)1.70x

Net Income / Employee (Annual)$2,133,900

EV / Revenue (TTM)2.74x

Net Interest Coverage (TTM)34.48x

ROA (TTM)72.27%

EPS Growth QoQ (YoY)-73.08%

EV / EBITDA (TTM)8.60x

EPS Incl Extra (Annual)$19.48

Current Ratio (Annual)2.42x

Quick Ratio (Quarterly)1.58x

3-Month Avg Trading Volume0.37M

52-Week Price Return18.24%

EV / Free Cash Flow (Annual)10.03x

P/E Incl Extra (TTM)2.42x

Revenue / Employee (TTM)$1,609,200

Tangible BV / Share (Quarterly)$17.77

P/S Ratio (Annual)2.65x

Asset Turnover (Annual)0.57x

52-Week High$52.24

Operating Margin (5Y Avg)-3.21%

EPS Excl Extra (Annual)$19.48

CapEx CAGR (5Y)-22.97%

26-Week Price Return34.69%

Quick Ratio (Annual)2.08x

13-Week Price Return54.68%

Total Debt / Equity (Annual)0.13x

Current Ratio (Quarterly)1.94x

Enterprise Value$758.96M

Revenue / Share Growth (5Y)89.25%

Asset Turnover (TTM)0.62x

Book Value / Share Growth (5Y)100.65%

Revenue / Employee (Annual)$1,710,900

Inventory Turnover (Annual)2.24x

Pretax Margin (Annual)41.40%

Cash / Share (Annual)$8.46

3-Month Return Std Dev42.59%

Gross Margin (5Y Avg)94.95%

Net Income / Employee (TTM)$1,871,600

EBITDA Interim CAGR (5Y)-22.31%

ROE (Last FY)93.75%

Net Interest Coverage (Annual)47.82x

EPS Basic Excl Extra (Annual)$19.48

P/FCF (TTM)9.85x

Receivables Turnover (TTM)5.77x

EV / Free Cash Flow (TTM)83.94x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$16.04

Receivables Turnover (Annual)6.30x

ROI (TTM)84.13%

P/S Ratio (TTM)2.82x

Pretax Margin (5Y Avg)-6.04%

Revenue / Share (Annual)$15.62

Tangible BV / Share (Annual)$20.03

Forward P/E9.93x

Price vs S&P 500 (52W)-0.32%

P/E Ratio (TTM)2.42x

EPS Growth TTM (YoY)196.12%

Year-to-Date Return8.52%

5-Day Price Return3.04%

EPS Normalized (Annual)$19.48

ROA (5Y Avg)1.28%

Net Profit Margin (Annual)124.72%

Month-to-Date Return26.27%

Cash Flow / Share (TTM)$-0.14

EBITD / Share (Annual)$6.79

Operating Margin (Annual)42.63%

LT Debt / Equity (Annual)0.06x

P/CF (TTM)9.83x

ROI (5Y Avg)-17.10%

P/E Excl Extra (TTM)2.42x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$16.04

P/TBV (Quarterly)2.18x

P/B Ratio (Annual)1.99x

Inventory Turnover (TTM)1.92x

Pretax Margin (TTM)30.92%

Book Value / Share (Annual)$21.38

Price vs S&P 500 (13W)52.72%

Beta1.21x

P/FCF (Annual)10.32x

Revenue / Share (TTM)$14.14

ROE (TTM)96.49%

52-Week Low$24.95

vGradeB

gGradeC

mGradeB

vgmGradeB

RIGL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$0.08	$0.88	+1266.80%(+$0.96)
Q1 2026	May 5, 2026	$0.87	$0.44	-49.54%(-$0.43)
Q4 2025	Mar 3, 2026	$1.20	$1.12	-6.80%(-$0.08)
Q3 2025	Nov 4, 2025	$0.94	$1.46	+56.03%(+$0.52)
Q2 2025	Aug 5, 2025	$1.41	$3.28	+133.45%(+$1.87)

RIGL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

4.09

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
RIGLRigel Pharmaceuticals Inc. (New)	B	C	B	$46.48
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Rigel Pharmaceuticals Inc. (New)

Rigel Pharmaceuticals develops small-molecule therapeutics for autoimmune, cancer, and viral diseases. The company markets TAVALISSE, an oral SYK inhibitor, and generates revenue through a partnership with AstraZeneca for an oral rheumatoid arthritis candidate, earning royalties and milestone payments. Its pipeline includes additional candidates targeting SYK and JAK pathways.